by Admin | Sep 25, 2020 | Portfolio News
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant...
by Admin | Sep 25, 2020 | Portfolio News
SAB to provide strategic guidance for the global development of Clover’s COVID-19 vaccine program Comprised of prominent vaccine and industry experts from around the world September 25, 2020 07:30 AM Eastern Daylight Time CHENGDU, China.–(BUSINESS...
by Admin | Sep 14, 2020 | Delos News, Portfolio News
BEDFORD, Mass., Sept. 14, 2020 /PRNewswire/ — Rejoni announced today that it has closed a $15 million Series A financing. The round was led by Ascension Ventures, with additional participation from Delos Capital and Sparta Group. Rejoni is using its...
by Admin | Sep 1, 2020 | Portfolio News
ATLANTA, Sept. 1, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today the publication of preclinical...
by Admin | Jul 8, 2020 | Portfolio News
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00...
by Admin | Jun 19, 2020 | Portfolio News
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019 GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical...